Open Market Insiders Trades
This list includes insiders general transaction with codes filed in Form 4 from SEC:
- P - Open market or private purchase of non-derivative or derivative security
- S - Open market or private sale of non-derivative or derivative security
- V - Transaction voluntarily reported earlier than required
Ticker | Insider | Transaction Type | Ownership Type | Shares Traded | Value / Price | Filing Date |
---|---|---|---|---|---|---|
ABT
|
Heather L Mason
Executive Vice President |
SELL
Open market or private sale
|
Direct | 1,912 Reduced 3.1% |
$86,059
$45.01 p/Share
|
Feb 28
2017 |
ABT
|
Jaime Contreras
Senior Vice President |
SELL
Open market or private sale
|
Direct | 13,155 Reduced 22.34% |
$592,107
$45.01 p/Share
|
Feb 28
2017 |
RARX
|
Novartis Bioventures LTD
> 10% Shareholder |
SELL
Open market or private sale
|
Direct | 7,847 Reduced 0.32% |
$163,688
$20.86 p/Share
|
Feb 28
2017 |
NEM
|
E Randall Engel
EVP, Strategic Development |
SELL
Open market or private sale
|
Direct | 2,356 Reduced 1.14% |
$84,392
$35.82 p/Share
|
Feb 27
2017 |
IBCP
|
Charles C Van Loan
Director |
SELL
Open market or private sale
|
Direct | 10,417 Reduced 12.01% |
$228,341
$21.92 p/Share
|
Feb 27
2017 |
NP
|
Armin Schwinn
SVP, Mng Dir, Neenah Germany |
SELL
Open market or private sale
|
Direct | 3,416 Reduced 78.62% |
$265,150
$77.62 p/Share
|
Feb 27
2017 |
NP
|
Steven S Heinrichs
SVP, General Counsel & Sec |
SELL
Open market or private sale
|
Direct | 6,010 Reduced 26.95% |
$454,476
$75.62 p/Share
|
Feb 27
2017 |
SNPS
|
Sudhindra Kankanwadi
Chief Accounting Officer |
SELL
Open market or private sale
|
Direct | 9,499 Reduced 82.0% |
$685,543
$72.17 p/Share
|
Feb 27
2017 |
LLY
|
Lilly Endowment Inc |
SELL
Open market or private sale
|
Direct | 225,000 Reduced 0.18% |
$18,688,499
$83.06 p/Share
|
Feb 27
2017 |
INTU
|
Brad D Smith
Director |
SELL
Open market or private sale
|
Direct | 103,445 Reduced 33.18% |
$13,067,172
$126.32 p/Share
|
Feb 27
2017 |
ARE
|
Thomas J Andrews
Co-President |
SELL
Open market or private sale
|
Direct | 5,000 Reduced 4.03% |
$603,000
$120.6 p/Share
|
Feb 27
2017 |
PRTA
|
Christopher S Henney
Director |
SELL
Open market or private sale
|
Direct | 5,989 Reduced 100.0% |
$342,331
$57.16 p/Share
|
Feb 27
2017 |
HD
|
Ann Marie Campbell
Senior EVP |
SELL
Open market or private sale
|
Direct | 7,000 Reduced 10.74% |
$1,017,030
$145.29 p/Share
|
Feb 27
2017 |
DHR
|
Angela S Lalor
SVP, Human Resources |
SELL
Open market or private sale
|
Direct | 6,044 Reduced 10.05% |
$520,993
$86.2 p/Share
|
Feb 27
2017 |
DHR
|
Daniel L Comas
EVP |
SELL
Open market or private sale
|
Direct | 10,250 Reduced 6.1% |
$882,422
$86.09 p/Share
|
Feb 27
2017 |
DJCO
|
John Patrick Et Al Guerin
Director |
SELL
Open market or private sale
|
Indirect | 301 Reduced 0.1% |
$64,866
$215.5 p/Share
|
Feb 27
2017 |
DJCO
|
John Patrick Et Al Guerin
Director |
SELL
Open market or private sale
|
Indirect | 1 Reduced 0.0% |
$217
$217.0 p/Share
|
Feb 27
2017 |
RARX
|
Novartis Bioventures LTD
> 10% Shareholder |
SELL
Open market or private sale
|
Direct | 57,844 Reduced 2.28% |
$1,212,410
$20.96 p/Share
|
Feb 27
2017 |
BMY
|
Theodore R. Samuels Ii
Director |
BUY
Open market or private purchase
|
Direct | 12,000 Added 50.0% |
$681,240
$56.77 p/Share
|
Feb 27
2017 |
MICS
|
Bernardo Melo
Chief Revenue Officer |
BUY
Open market or private purchase
|
Direct | 5,000 Added 0.91% |
$2,650
$0.53 p/Share
|
Feb 24
2017 |
MICS
|
Gary Kevin Atkinson
Chief Executive Officer |
BUY
Open market or private purchase
|
Direct | 5,000 Added 1.6% |
$2,650
$0.53 p/Share
|
Feb 24
2017 |
NEE
|
William H Swanson
Director |
BUY
Open market or private purchase
|
Direct | 3,860 Added 13.29% |
$497,400
$128.86 p/Share
|
Feb 24
2017 |
MDC
|
David E Blackford
Director |
SELL
Open market or private sale
|
Direct | 16,250 Reduced 54.85% |
$479,212
$29.49 p/Share
|
Feb 24
2017 |
CSCO
|
Chris Dedicoat
EVP, Worldwide Sales & Fld Ops |
SELL
Open market or private sale
|
Direct | 34,597 Reduced 13.11% |
$1,180,450
$34.12 p/Share
|
Feb 24
2017 |
ARE
|
Thomas J Andrews
Co-President |
SELL
Open market or private sale
|
Direct | 5,000 Reduced 3.88% |
$598,400
$119.68 p/Share
|
Feb 24
2017 |
DHR
|
Robert S Lutz
SVP-Chief Accounting Officer |
SELL
Open market or private sale
|
Direct | 37,870 Reduced 59.1% |
$3,241,672
$85.6 p/Share
|
Feb 24
2017 |
INTC
|
Diane M Bryant
EVP and Group President |
SELL
Open market or private sale
|
Direct | 55,821 Reduced 34.22% |
$2,028,535
$36.34 p/Share
|
Feb 24
2017 |
UPS
|
Teri P Mc Clure
CHRO & SVP, Labor Relations |
SELL
Open market or private sale
|
Direct | 4,500 Reduced 100.0% |
$471,825
$104.85 p/Share
|
Feb 24
2017 |
NEM
|
William N Mac Gowan
EVP, Human Resources |
SELL
Open market or private sale
|
Direct | 2,006 Reduced 2.26% |
$72,838
$36.31 p/Share
|
Feb 24
2017 |
TSLA
|
Antonio J. Gracias
Director |
SELL
Open market or private sale
|
Direct | 5,466 Reduced 100.0% |
$1,392,245
$254.71 p/Share
|
Feb 24
2017 |
RTX
|
Robert J. Bailey
Corporate VP, Controller |
SELL
Open market or private sale
|
Direct | 1,022 Reduced 100.0% |
$114,730
$112.26 p/Share
|
Feb 24
2017 |
RARX
|
Novartis Bioventures LTD
> 10% Shareholder |
SELL
Open market or private sale
|
Direct | 5,398 Reduced 0.21% |
$112,980
$20.93 p/Share
|
Feb 24
2017 |
MDC
|
David E Blackford
Director |
SELL
Open market or private sale
|
Direct | 5,000 Reduced 27.21% |
$147,000
$29.4 p/Share
|
Feb 23
2017 |
MDC
|
David E Blackford
Director |
SELL
Open market or private sale
|
Direct | 5,000 Reduced 27.21% |
$145,900
$29.18 p/Share
|
Feb 23
2017 |
MAS
|
Lisa A Payne
Director |
SELL
Open market or private sale
|
Direct | 1,949 Reduced 3.18% |
$66,052
$33.89 p/Share
|
Feb 23
2017 |
SNPS
|
Steven Walske
Director |
SELL
Open market or private sale
|
Direct | 9,074 Reduced 34.69% |
$644,435
$71.02 p/Share
|
Feb 23
2017 |
NEM
|
E Randall Engel
EVP, Strategic Development |
SELL
Open market or private sale
|
Direct | 675 Reduced 0.31% |
$24,665
$36.54 p/Share
|
Feb 23
2017 |
FSLR
|
Paul J Kaleta
EVP, Genl Counsel & Secretary |
SELL
Open market or private sale
|
Direct | 8,492 Reduced 26.38% |
$286,095
$33.69 p/Share
|
Feb 23
2017 |
PLNT
|
Christopher Rondeau |
SELL
Open market or private sale
|
Indirect | 20,000 Reduced 100.0% |
$421,800
$21.09 p/Share
|
Feb 23
2017 |
ABT
|
Funck, Jr. Robert E.
EXECUTIVE VICE PRESIDENT |
SELL
Open market or private sale
|
Direct | 25,500 Reduced 21.69% |
$1,160,250
$45.5 p/Share
|
Feb 23
2017 |
CSCO
|
Arun Sarin
Director |
SELL
Open market or private sale
|
Indirect | 13,869 Reduced 49.43% |
$472,378
$34.06 p/Share
|
Feb 23
2017 |
CSCO
|
Roderick C Mcgeary
Director |
SELL
Open market or private sale
|
Direct | 10,000 Reduced 7.53% |
$340,700
$34.07 p/Share
|
Feb 23
2017 |
CSCO
|
John T Chambers
Executive Chairman |
SELL
Open market or private sale
|
Direct | 250,000 Reduced 17.0% |
$8,515,000
$34.06 p/Share
|
Feb 23
2017 |
CSCO
|
John T Chambers
Executive Chairman |
SELL
Open market or private sale
|
Indirect | 45,538 Reduced 50.0% |
$1,550,569
$34.05 p/Share
|
Feb 23
2017 |
ARE
|
Thomas J Andrews
Co-President |
SELL
Open market or private sale
|
Direct | 5,000 Reduced 3.73% |
$594,200
$118.84 p/Share
|
Feb 23
2017 |
SQ
|
Francoise Brougher
Business Lead |
SELL
Open market or private sale
|
Direct | 115,385 Reduced 55.38% |
$1,951,160
$16.91 p/Share
|
Feb 23
2017 |
TSLA
|
John Douglas Field
Senior VP, Engineering |
SELL
Open market or private sale
|
Direct | 500 Reduced 3.3% |
$128,770
$257.54 p/Share
|
Feb 23
2017 |
HD
|
Carol B Tome
CFO & EVP - Corp. Services |
SELL
Open market or private sale
|
Direct | 100,000 Reduced 15.38% |
$14,525,000
$145.25 p/Share
|
Feb 23
2017 |
HD
|
Timothy M Crow
EVP - Human Resources |
SELL
Open market or private sale
|
Direct | 88,253 Reduced 30.16% |
$12,846,990
$145.57 p/Share
|
Feb 23
2017 |
RARX
|
Novartis Bioventures LTD
> 10% Shareholder |
SELL
Open market or private sale
|
Direct | 4,999 Reduced 0.2% |
$105,179
$21.04 p/Share
|
Feb 23
2017 |